Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice

Neurobiology of Disease

Volumn 48, Issue 1, 2012, Pages 40-51

  Milnerwood, Austen J ^a,b   Kaufman, Alexandra M ^a   Sepers, Marja D ^a,b   Gladding, Clare M ^a,b   Zhang, Lily ^a   Wang, Liang ^a   Fan, Jing ^a,b   Coquinco, Ainsley ^a,b   Qiao, Joy Yi ^a   Lee, Hwan ^a   Wang, Yu Tian ^a,b   Cynader, Max ^a   Raymond, Lynn A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Coculture; Corticostriatal; Electrophysiology; Excitotoxicity; Extrasynaptic; GluN2A; GluN2B; Glutamate; Huntington's disease; Microfluidic isolation chamber; Neurodegeneration; NMDA receptor; PCREB; Striatal medium spiny neuron; Striatum; YAC128

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HUNTINGTIN; IFENPRODIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; VESICULAR GLUTAMATE TRANSPORTER 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN CORTEX; BRAIN REGION; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; GENOTYPE; HIPPOCAMPUS; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SYNAPSE; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS;

ANIMALS; APOPTOSIS; CEREBRAL CORTEX; COCULTURE TECHNIQUES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; HUNTINGTON DISEASE; MEMANTINE; MICE; MICE, TRANSGENIC; NEURONS; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 84863773618     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.05.013     Document Type: Article

References (58)

1. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
2. Beal M.F., Kowall N.W., Swartz K.J., Ferrante R.J. Homocysteic acid lesions in rat striatum spare somatostatin-neuropeptide Y (NADPH-diaphorase) neurons. Neurosci. Lett. 1990, 108:36-42.
3. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181-4192.
4. Bengtson C.P., Dick O., Bading H. A quantitative method to assess extrasynaptic NMDA receptor function in the protective effect of synaptic activity against neurotoxicity. BMC Neurosci. 2008, 9:11.
5. Berberich S., Punnakkal P., Jensen V., Pawlak V., Seeburg P.H., Hvalby O., Kohr G. Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation. J. Neurosci. 2005, 25:6907-6910.
6. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 2001, 66:525-539.
7. Chen H.S., Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 2006, 97:1611-1626.
8. Chen N., Luo T., Wellington C., Metzler M., McCutcheon K., Hayden M.R., Raymond L.A. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 1999, 72:1890-1898.
9. Cowan C.M., Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Biol. 2006, 75:25-71.
10. Coyle J.T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263:244-246.
11. Fan M.M., Raymond L.A. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 2007, 81:272-293.
12. Fan M.M., Fernandes H.B., Zhang L.Y., Hayden M.R., Raymond L.A. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. J. Neurosci. 2007, 27:3768-3779.
13. Fan J., Cowan C.M., Zhang L.Y., Hayden M.R., Raymond L.A. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J. Neurosci. 2009, 29:10928-10938.
14. Fan J., Vasuta O.C., Zhang L.Y., Wang L., George A., Raymond L.A. N-methyl-d-aspartate receptor subunit- and neuronal-type dependence of excitotoxic signaling through post-synaptic density 95. J. Neurochem. 2010, 115:1045-1056.
15. Fernandes H.B., Baimbridge K.G., Church J., Hayden M.R., Raymond L.A. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci. 2007, 27:13614-13623.
16. Gladding C.M., Raymond L.A. Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol. Cell. Neurosci. 2011, 48:308-320.
17. Gouix E., Leveille F., Nicole O., Melon C., Had-Aissouni L., Buisson A. Reverse glial glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor activation. Mol. Cell. Neurosci. 2009, 40:463-473.
18. Graham R.K., Pouladi M.A., Joshi P., Lu G., Deng Y., Wu N.P., Figueroa B.E., Metzler M., Andre V.M., Slow E.J., Raymond L., Friedlander R., Levine M.S., Leavitt B.R., Hayden M.R. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 2009, 29:2193-2204.
19. Greer P.L., Greenberg M.E. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 2008, 59:846-860.
20. Hardingham G.E., Bading H. Coupling of extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated. Biochim. Biophys. Acta 2002, 1600:148-153.
21. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11:682-696.
22. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
23. Hatton C.J., Paoletti P. Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron 2005, 46:261-274.
24. Heng M.Y., Detloff P.J., Wang P.L., Tsien J.Z., Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 2009, 29:3200-3205.
25. Ivanov A., Pellegrino C., Rama S., Dumalska I., Salyha Y., Ben-Ari Y., Medina I. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J. Physiol. 2006, 572:789-798.
26. Kaech S., Banker G. Culturing hippocampal neurons. Nat. Protoc. 2006, 1:2406-2415.
27. Kaufman A.M., Milnerwood A.J., Sepers M.D., Coquinco A., She K., Wang L., Lee H., Craig A.M., Cynader M., Raymond L.A. Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J. Neurosci. 2012, 32:3992-4003.
28. Kim M.J., Dunah A.W., Wang Y.T., Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron 2005, 46:745-760.
29. Kohr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res. 2006, 326:439-446.
30. Leveille F., El Gaamouch F., Gouix E., Lecocq M., Lobner D., Nicole O., Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008, 22:4258-4271.
31. Leveille F., Papadia S., Fricker M., Bell K.F., Soriano F.X., Martel M.A., Puddifoot C., Habel M., Wyllie D.J., Ikonomidou C., Tolkovsky A.M., Hardingham G.E. Suppression of the intrinsic apoptosis pathway by synaptic activity. J. Neurosci. 2010, 30:2623-2635.
32. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., Chesselet M.F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 1999, 58:515-532.
33. Li L., Murphy T.H., Hayden M.R., Raymond L.A. Enhanced striatal NR2B-containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 2004, 92:2738-2746.
34. Liu Y., Wong T.P., Aarts M., Rooyakkers A., Liu L., Lai T.W., Wu D.C., Lu J., Tymianski M., Craig A.M., Wang Y.T. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 2007, 27:2846-2857.
35. Mammen A.L., Huganir R.L., O'Brien R.J. Redistribution and stabilization of cell surface glutamate receptors during synapse formation. J. Neurosci. 1997, 17:7351-7358.
36. Mandal M., Wei J., Zhong P., Cheng J., Duffney L.J., Liu W., Yuen E.Y., Twelvetrees A.E., Li S., Li X.J., Kittler J.T., Yan Z. Impaired {alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking and function by mutant huntingtin. J. Biol. Chem. 2011, 286:33719-33728.
37. McGeer E.G., McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976, 263:517-519.
38. Milnerwood A.J., Raymond L.A. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J. Physiol. 2007, 585:817-831.
39. Milnerwood A.J., Raymond L.A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 2010, 33:513-523.
40. Milnerwood A.J., Cummings D.M., Dallerac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1690-1703.
41. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W., Vasuta O.C., Graham R.K., Hayden M.R., Murphy T.H., Raymond L.A. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
42. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108:193-199.
43. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Vincent Chen H.S., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
44. Orth M., Schippling S., Schneider S.A., Bhatia K.P., Talelli P., Tabrizi S.J., Rothwell J.C. Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J. Neurol. Neurosurg. Psychiatry 2010, 81:267-270.
45. Papadia S., Soriano F.X., Leveille F., Martel M.A., Dakin K.A., Hansen H.H., Kaindl A., Sifringer M., Fowler J., Stefovska V., McKenzie G., Craigon M., Corriveau R., Ghazal P., Horsburgh K., Yankner B.A., Wyllie D.J., Ikonomidou C., Hardingham G.E. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 2008, 11:476-487.
46. Park J.W., Vahidi B., Taylor A.M., Rhee S.W., Jeon N.L. Microfluidic culture platform for neuroscience research. Nat. Protoc. 2006, 1:2128-2136.
47. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 2008, 79:874-880.
48. Raymond L.A., Andre V.M., Cepeda C., Gladding C.M., Milnerwood A.J., Levine M.S. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011, 198:252-273.
49. Schippling S., Schneider S.A., Bhatia K.P., Munchau A., Rothwell J.C., Tabrizi S.J., Orth M. Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol. Psychiatry 2009, 65:959-965.
50. Shehadeh J., Fernandes H.B., Zeron Mullins M.M., Graham R.K., Leavitt B.R., Hayden M.R., Raymond L.A. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 2006, 21:392-403.
51. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
52. Smith A.D., Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 1990, 13:259-265.
53. Starling A.J., Andre V.M., Cepeda C., de Lima M., Chandler S.H., Levine M.S. Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J. Neurosci. Res. 2005, 82:377-386.
54. Tapia L., Milnerwood A., Guo A., Mills F., Yoshida E., Vasuta C., Mackenzie I.R., Raymond L., Cynader M., Jia W., Bamji S.X. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. J. Neurosci. 2011, 31:11126-11132.
55. Twelvetrees A.E., Yuen E.Y., Arancibia-Carcamo I.L., MacAskill A.F., Rostaing P., Lumb M.J., Humbert S., Triller A., Saudou F., Yan Z., Kittler J.T. Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron 2010, 65:53-65.
56. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
57. Zeron M.M., Fernandes H.B., Krebs C., Shehadeh J., Wellington C.L., Leavitt B.R., Baimbridge K.G., Hayden M.R., Raymond L.A. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 2004, 25:469-479.
58. 2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol. Dis. 2008, 31:80-88.